TAK - TAKEDA PHARMACEUTICAL CO LTD

QQQ $ 476.00 $ 5.61 (1.19 %)

DIA $ 416.44 $ 2.30 (0.56 %)

SPY $ 563.62 $ 5.33 (0.95 %)

TLT $ 96.60 $ -1.04 (-1.07 %)

GLD $ 231.30 $ -1.66 (-0.71 %)

Previous Close

$ 14.89

Open

$ 14.86

Bid

$ 14.88 x 1,298

Ask

-- x --

Day's Range

$ 14.81 - $ 14.92

52 Week Range

$ 12.58 - $ 16.39

Volume

1,859,532

Average Volume

Market Cap

25.15B

Beta (5Y Monthly)

$ 0.60

PE Ratio (TTM)

$ 26.40

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

ascendis-hypoparathyroidism-drug-scores-fda-approval-as-first-and-only-treatment-replacing-takedas-drug-discontinued-due-to-supply-issues

Ascendis' Hypoparathyroidism Drug Scores F...
08/12/2024 14:42:45

FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous...

why-is-japanese-drugmaker-takeda-pharmaceutical-stock-trading-higher-on-wednesday

Why Is Japanese Drugmaker Takeda Pharmaceu...
08/07/2024 18:29:04

Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP pa...

The European Commission Approves Takeda's ...
08/07/2024 10:51:35

Takeda 2024 Outlook, Reaffirmed: Expects R...
07/31/2024 06:28:57

FY2024 Outlook (unchanged from May 2024) (Billion yen, except percentages and per share

Takeda Pharmaceutical Q1 Core EPS ¥176 Up ...
07/31/2024 06:23:54

newly-listed-psoriasis-focused-alumis-attracts-analysts-attention-with-promising-lead-program-and-modest-valuation

Newly-Listed Psoriasis-Focused Alumis Attr...
07/24/2024 19:18:10

Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis an...

Dr. Reddy's Signs Non-Exclusive Patent Lic...
07/18/2024 12:14:02

eli-lillys-32b-morphic-deal-is-crucial-has-strategic-merit-despite-investor-attention-on-obesity-analyst

Eli Lilly's $3.2B Morphic Deal Is 'Crucial...
07/09/2024 18:59:12

Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and ...

blackstone-nears-22b-deal-for-sale-of-japanese-supplement-maker-alinamin-report

Blackstone Nears $2.2B Deal For Sale Of Ja...
07/02/2024 12:22:21

Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone a...

Takeda's LIVTENCITY Gains Approval in Japa...
06/24/2024 07:10:14

Takeda ((TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Wel...

Reported Earlier, Takeda's Mezagitamab Sho...
06/24/2024 07:09:07

Takeda ((TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating...

Takeda Announces European Commission Appro...
06/21/2024 20:00:59

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial− FRUZAQLA (fruquintinib) is the First Novel Targeted ...

Health Canada Expanded Marketing Authoriza...
06/21/2024 12:17:20

HyQvia®, which may be administered at home, will provide children and adolescents living with immunodeficiencies with a new tre...

nextera-energy-lennar-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session

NextEra Energy, Lennar And Other Big Stock...
06/18/2024 12:39:31

Takeda To Present Long-Term Data From Phas...
06/18/2024 12:06:48

Favorable Findings from the Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for...

why-ovid-therapeutics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Ovid Therapeutics Shares Are Trading L...
06/17/2024 17:21:47

whats-going-on-with-ovid-therapeutics-after-takedas-two-phase-3-epilepsy-studies-fail

What's Going On With Ovid Therapeutics Aft...
06/17/2024 12:58:59

Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In ...

japan-pharma-giant-takedas-anti-seizure-treatment-flunks-in-two-late-stage-studies

Japan Pharma Giant Takeda's Anti-Seizure T...
06/17/2024 12:41:44

Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet ...

After Takeda's Phase 3 Topline Study Resul...
06/17/2024 11:01:02

Takeda Announced Topline Data From SKYLINE...
06/17/2024 10:48:35

SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed ...